Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue Evolus (NASDAQ: EOLS) reported preliminary unaudited net revenue of $88.6M–$90.6M for Q4 2025 (up 12%–15% YoY) and $295.5M–$297.5M for full-year 2025 (up 11%–12% YoY). The company reaffirmed Q4 2025 non-GAAP operating income of $5M–$7M and provided 2026 net revenue guidance of $327M–$337M (11%–13% growth vs. preliminary 2025). Evolysse and Estyme injectable HA gels are expected to contribute 10%–12% of 2026 revenue. Cash and equivalents were $53M as of Dec 31, 2025. Long-term outlook updated to $450M–$500M revenue for 2028 with 13%–15% non-GAAP operating margins.

#EOLS Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue

www.stocktitan.net/news/EOLS/evolus-announc...

📌 #virusinfo #EOLs

Trade Alerts, Thursday November 6, 2025 – Crystal Equity Research

Small-cap stocks in new ADX uptrend, Thu Nov 6th - #ATPC #UFPT #SRTS #RIGL #PDSB #FRBA #EOLS #BFST #ACNT #TDC #MITT #FSLY #DBI #BGS - More: crystalequityresearch.com/trade-alerts... - #smallcap

#EOLS Evolus Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/EOLS/evolus-reports...

Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch Evolus (NASDAQ: EOLS) has appointed Dr. Benjamin Eskenazi as lead consultant for the national launch of their Evolysse™ filler line. Dr. Eskenazi, founder of Miami Beach's Avabello Aesthetics, will provide expertise and support to aesthetic providers implementing the newly FDA-approved hyaluronic acid dermal fillers.The Evolysse™ line features innovative Cold-X™ technology for longer-lasting results and includes Evolysse™ Form and Evolysse™ Smooth, with additional products planned for launch in 2026 and 2027. This partnership demonstrates Evolus' commitment to patient safety and provider education in the aesthetic medicine field.

#EOLS Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch

www.stocktitan.net/news/EOLS/top-miami-plas...

Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp Evolus (NASDAQ: EOLS) announced positive topline results from its U.S. pivotal study of Evolysse™ Sculpt, an injectable hyaluronic acid gel product for mid-face volume restoration. The study demonstrated statistical superiority over Restylane®-Lyft, with Evolysse™ Sculpt achieving a 90.9% responder rate compared to 83.3% for Restylane®-Lyft.The company has submitted a Premarket Approval (PMA) application to the FDA, with approval expected in the second half of 2026. The product, manufactured using innovative Cold-X™ technology, showed a favorable safety profile with no treatment-related serious adverse events. This development marks a significant expansion beyond Evolus' existing Jeuveau® product line.

#EOLS Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp

www.stocktitan.net/news/EOLS/evolus-announc...

304-Patient Trial Data: Evolus Challenges Restylane with New Long-lasting Mid-Face Filler Technology Aesthetic company Evolus submits PMA for Evolysse Sculpt hyaluronic acid gel for mid-face volume restoration. 304-patient trial vs Restylane-Lyft completed. FDA decision expected H2 2026.

#EOLS Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product

www.stocktitan.net/news/EOLS/evolus-announc...

Evolus (EOLS) Q2 Revenue Rises 4% | The Motley Fool

#EOLS #4508f209-018c-4bae-88ae-c9c8f600d4c8 #data-news

Origin | Interest | Match

New JAMA Research Reveals Jeuveau Achieves 93% Better Results Than Leading Botox Alternatives Independent study shows Jeuveau delivers faster onset and stronger peak effect vs Botox, Dysport, and Xeomin in aesthetic treatments. See full clinical data.

#EOLS Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins

www.stocktitan.net/news/EOLS/evolus-announc...

🚨 Institutions #optionsvolume surge detected! Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.

🚨 Institutions #optionsvolume surge detected!

Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #GPRO 12178.8x
2. #BMNR 5623.8x
3. #DNUT 4056.8x
4. #ALLO 279.0x
5. #EOLS 179.2x

#OptionFlow #OptionsTrading #Trading

Evolus CFO Departs After Driving Record Growth: What This Leadership Change Means for the Beauty Company Evolus CFO exits for private sector role as company reports strong momentum and record revenues. Finance team to ensure smooth transition while successor search begins. Learn more.

#EOLS Evolus Announces Departure of its Chief Financial Officer

www.stocktitan.net/news/EOLS/evolus-announc...

Clinical Trial Breakthrough: Evolysse Outperforms Leading Dermal Filler with Less Product Used New clinical data reveals Evolysse's superior performance vs Restylane-L in wrinkle correction, with 80% patient satisfaction and better durability. See full results.

#EOLS Evolus Announces Publication of U.S. Pivotal Study for Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

www.stocktitan.net/news/EOLS/evolus-announc...

Evolus Reports First Quarter 2025 Results Evolus (NASDAQ: EOLS) reported strong Q1 2025 financial results with global net revenue of $68.5 million, up 15.5% year-over-year. The company posted a GAAP operating loss of $15.2 million and a non-GAAP operating loss of $5.5 million. Despite operating in a slower market, Evolus gained meaningful market share and successfully launched Evolysse™ in Q2.Key highlights include: over 16,000 total customers with a 70% reorder rate, Evolus Rewards™ program growing to over 1.1 million members (39% YoY increase), and record-high quarterly redemptions exceeding 220,000. The company reaffirmed its 2025 revenue guidance of $345-355 million, with Evolysse™ and Estyme® expected to contribute 8-10% of total revenue.Looking ahead, Evolus projects reaching $700 million in revenue by 2028 (27% CAGR from 2024) and achieving non-GAAP operating income margins of at least 20% by 2028.

#EOLS Evolus Reports First Quarter 2025 Results

www.stocktitan.net/news/EOLS/evolus-reports...

Evolus Lands Massive $250M Credit Deal: 350 Basis Point Savings Boost Bottom Line Just secured: Evolus strengthens financial position with $250M credit facility, cutting borrowing costs by 350bps. Zero dilution, enhanced flexibility. See full details.

#EOLS Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

www.stocktitan.net/news/EOLS/evolus-strengt...

Game-Changing Dermal Filler Outperforms Restylane in Clinical Trials: Evolus Expands Portfolio New Evolysse dermal fillers show superior results vs Restylane-L using innovative Cold-X technology. Clinical trials reveal breakthrough efficacy with less product.

#EOLS Evolus Announces Commercial Launch of Evolysse™

www.stocktitan.net/news/EOLS/evolus-announc...

Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels Evolus, Inc., a performance beauty company with a focus on building an aesthetic portfolio, today announced the launch of its bold new campaign,“ Drop the F Word,” ahead of the upcoming commercial launch of Evolysse™. Designed to challenge outdated perceptions and language in the aesthetics industry, the campaign introduces Evolysse™, a collection of injectable...

#EOLS Evolus Launches “Drop the F Word” Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels

www.stocktitan.net/news/EOLS/evolus-launche...

The chart that made me interested in #EOLS and the chart that makes me excited about its future potential

Evolus Smashes Revenue Expectations: How Early Profitability Changes Its Growth Trajectory Evolus reports 30% revenue growth to $79M in Q4, achieves profitability one year ahead of schedule, and maintains strong 2025 guidance targeting 33% growth.

#EOLS Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

www.stocktitan.net/news/EOLS/evolus-reports...

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels Evolus (NASDAQ: EOLS) has received FDA approval for Evolysse™ Form and Evolysse™ Smooth, two injectable hyaluronic acid (HA) gels representing the first major technological breakthrough in dermal fillers in a decade. The company plans to launch these products in Q2 2025, expanding its addressable market by 78% to approximately $6 billion.The products utilize innovative Cold-X™ technology designed to better preserve the HA molecule structure for long-lasting results. In clinical trials involving 140 patients, both products demonstrated statistical superiority compared to Restylane®-L. The company aims to achieve at least $700 million in net revenue and non-GAAP operating income margin of at least 20% by 2028.Two additional products, Evolysse™ Sculpt and Evolysse™ Lips, are planned for launch in 2026 and 2027 respectively. The company also received EU MDR approval for four HA gels under the brand name Estyme®, with European launch planned for second half of 2025.

#EOLS Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

www.stocktitan.net/news/EOLS/evolus-announc...

Evolus Reports Record Q4 Revenue, Expects FDA Approval for New Injectable HA Gels in 2025 Evolus achieves $79M in Q4 revenue, up 30% YoY. Company anticipates FDA approval for Evolysse™ products within 90 days and projects 30-33% revenue growth in 2025.

#EOLS Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance

www.stocktitan.net/news/EOLS/evolus-announc...

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#FNGR, #LUMN, #SOUN, #EOLS, #NVDL

#OptionFlow #OptionsTrading #Trading

Just In: ( NASDAQ: #EOLS ) EOLS Price Target Alert: $20.00. Issued by Barclays

#StockMarket #News

NEWS: ( NASDAQ: #EOLS ) (EOLS) Investment Analysis and Advice

#StockMarket #News